Samrat Pharmachem share price
You have to be logged in to add this to Watchlist.- ₹356.00(-1.40%)June 30, 2025 15:29:23 PM IST
- NSE
- BSE
- Vol : 5.62K (NSE + BSE)Last 20 day avg : 3.70 K
Samrat Pharmachem is trading -1.40% lower at Rs 356.00 as compared to its last closing price. Samrat Pharmachem has been trading in the price range of 378.95 & 356.00. Samrat Pharmachem has given -5.64% in this year & 5.79% in the last 5 days. Samrat Pharmachem has TTM P/E ratio 13.59 as compared to the sector P/E of 17.69.The company posted a net profit of -0.40 Crores in its last quarter.Listed peers of Samrat Pharmachem include Take Solutions (4.91%), Parnax Lab (-0.48%), Samrat Pharmachem (-1.40%).The Mutual Fund holding in Samrat Pharmachem was at -% in . The MF holding has - from the last quarter. The FII holding in Samrat Pharmachem was at 3.24% in 30 Jun 2022. The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Jun 30, 2025, 01:05 PM UTC
- Dividend YieldLower than industry0.28Annual dividends as a percentage of the stock price.
- P/BLower than historical values1.55The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values15.69Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility-0.02Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.14The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is not profitable- The company's revenue fell during March quarter by 13.88% from Rs 82.68 crore to Rs 71.20 crore, year-on-year
- Company has registered a loss of 0.40 cr vs a profit of 1.40 cr in the same quarter last year.
The debt to equity of the company is lower than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 428.17
- R2
- 459.08
- R3
- 508.17
- S1
- 348.17
- S2
- 299.08
- S3
- 268.17
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Take Solutions | Neutral | 8.97 | 4.91 | 132.69 | 169.54 | 6.09 | - | - |
| Parnax Lab | Moderately Bearish | 103.00 | -0.48 | 118.30 | 10.30 | 1.43 | - | 31.58 |
| Samrat Pharmachem | Bullish | 356.00 | -1.40 | 110.43 | 15.68 | 1.55 | 0.28 | - |
| Nutricircle | Bearish | 102.00 | -4.98 | 102.00 | 887.92 | 18.51 | - | 13.87 |
| Mercury Laboratories | Moderately Bullish | 843.45 | -1.47 | 102.50 | 32.66 | 1.92 | 0.41 | 7.06 |
- Promoter(s) holding is moderate at 49.09%
- Promoter(s) have increased the stake in the company in last 12 months
- FIIs are not invested in this company
- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-30 | Audited Results & Final Dividend |
| 2025-02-14 | Quarterly Results |
| 2024-11-14 | Quarterly Results |
| 2024-08-13 | Quarterly Results |
| 2024-05-30 | Audited Results & Final Dividend |
- IndustryBiotechnology & Drugs
- ISININE103E01016
- BSE Code530125
- NSE Code
Samrat Pharmachem is trading at 356.00 as on Mon Jun 30 2025 09:59:23. This is -1.40% lower as compared to its previous closing price of 361.05.
The market capitalization of Samrat Pharmachem is 110.43 Cr as on Mon Jun 30 2025 09:59:23.
The 52 wk high for Samrat Pharmachem is 646.00 whereas the 52 wk low is 302.05
Samrat Pharmachem can be analyzed on the following key metrics -
- TTM P/E: 13.59
- Sector P/E: 17.69
- Dividend Yield: 0.28%
- D/E ratio: 0.14
Samrat Pharmachem reported a net profit of 7.11 Cr in 2025.